Intracranial Meningeal Hemangiopericytomas: An Analysis of Factors Affecting Outcome from Multimodality Treatment of 39 Cases

Aim: To retrospectively evaluate outcome of patients with intracranial meningeal hemangiopericytomas (MHPCs) and to analyze various factors for recurrence and survival in these patients.

Materials and Methods: We retrospectively reviewed the clinical data of 39 patients undergoing microsurgical resection for MHPCs at our institute from 2009 to 2015.

Results: GTE was achieved in 27 (69.2%) patients, while 12 (30.8%) underwent STE. Twenty-five patients received radiotherapy (conventional RT-15; GKT-10). Twenty-one patients had low grade, while 18 had anaplastic variant. Twenty patients (51.3%) developed recurrences. Average recurrence-free survival (RFS) was 56 months (range, 12–180 months). Eight patients (20.5%) died during study period. The average overall survival (OS) was 77.2 months (range, 36–192 months). Two patients (5.1%) developed systemic metastases during follow-up. Patient age was not found to affect RF or OS. GTE was associated with prolonged RFS and OS, but the impact was not statistically significant (p values-0.160 & 0.414, respectively). Low tumor grade was associated with statistically significant longer RFS as well as OS (p values-0.049 & 0.013, respectively). Addition of adjuvant RT was associated with statistically significant prolongation of RFS (p value-0.016); however, it was not associated with statistically significant overall survival benefits (p value-0.758).

Conclusions: Our study suggests that extent of excision, low tumor grade, and addition of adjuvant RT have a positive impact on both RFS and OS; however, low grade and adjuvant RT were the only factors associated with statistically significant prolongation of RFS and only tumor grade was associated with statistically significant overall survival benefits.